GGG

GLYCOREX TRANSPLANTATION B

No trades
See on Supercharts
Market capitalization
‪56.42 M‬SEK
−0.412SEK
‪−30.36 M‬SEK
‪29.96 M‬SEK
‪53.13 M‬
Beta (1Y)
−0.63

About GLYCOREX TRANSPLANTATION B

CEO
Johan Laven
Headquarters
Lund
Founded
1995
ISIN
SE0000524530
FIGI
BBG000DL2DC4
Glycorex Transplantation AB engages in the research and development in the field of organ transplantation. The firm focuses mainly in kidney transplant and also in liver, heart, pancreas, lung, and stem cell transplant. Its product allows transplantation regardless of the blood types of donors and recipients. The company was founded by Kurt Gösta Ingemar Nilsson in 1996 and is headquartered in Lund, Sweden.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of GTAB.B is 0.920 SEK — it has increased by 12.20% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NGM exchange GLYCOREX TRANSPLANTATION B stocks are traded under the ticker GTAB.B.
GTAB.B stock is 60.10% volatile and has beta coefficient of −0.63. Check out the list of the most volatile stocks — is GLYCOREX TRANSPLANTATION B there?
Yes, you can track GLYCOREX TRANSPLANTATION B financials in yearly and quarterly reports right on TradingView.
GTAB.B stock has risen by 12.20% compared to the previous week, the month change is a 1.32% rise, over the last year GLYCOREX TRANSPLANTATION B has showed a 77.99% decrease.
GTAB.B net income for the last quarter is ‪−16.62 M‬ SEK, while the quarter before that showed ‪−5.48 M‬ SEK of net income which accounts for −203.47% change. Track more GLYCOREX TRANSPLANTATION B financial stats to get the full picture.
Today GLYCOREX TRANSPLANTATION B has the market capitalization of ‪60.56 M‬, it has increased by 3.56% over the last week.
No, GTAB.B doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, GTAB.B shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GLYCOREX TRANSPLANTATION B stock right from TradingView charts — choose your broker and connect to your account.
GTAB.B reached its all-time high on Apr 29, 2020 with the price of 20.700 SEK, and its all-time low was 0.750 SEK and was reached on Apr 3, 2024.
See other stocks reaching their highest and lowest prices.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GLYCOREX TRANSPLANTATION B technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GLYCOREX TRANSPLANTATION B stock shows the sell signal. See more of GLYCOREX TRANSPLANTATION B technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GLYCOREX TRANSPLANTATION B EBITDA is ‪−10.07 M‬ SEK, and current EBITDA margin is −33.67%. See more stats in GLYCOREX TRANSPLANTATION B financial statements.